` IBIO (Ibio Inc) vs S&P 500 Comparison - Alpha Spread

IBIO
vs
S&P 500

Over the past 12 months, IBIO has underperformed S&P 500, delivering a return of -65% compared to the S&P 500's +13% growth.

Stocks Performance
IBIO vs S&P 500

Loading
IBIO
S&P 500
Add Stock

Performance Gap
IBIO vs S&P 500

Loading
IBIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
IBIO vs S&P 500

Loading
IBIO
S&P 500
Add Stock

Competitors Performance
Ibio Inc vs Peers

S&P 500
IBIO
ABBV
AMGN
GILD
VRTX
Add Stock

Ibio Inc
Glance View

Market Cap
12.7m USD
Industry
Biotechnology

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

IBIO Intrinsic Value
0.21 USD
Overvaluation 73%
Intrinsic Value
Price
Back to Top